Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
Clinical trial NCT04850157 · UNKNOWN
Trial details
- NCT number
- NCT04850157
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-20
- Primary completion
- 2022-04-20
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.